| 6. Alcoholic Liver
Disease / F. Wong and L. Blendis |
page 502 |
Liver disease is the fourth commonest cause
of death in adults between the ages of 20 and 70 years in Canada. Alcohol is still the
commonest cause of chronic liver disease in this country. Not all those who abuse alcohol
develop liver damage: the incidence of cirrhosis among alcoholics is approximately 10-30%.
The mechanism for the predisposition of certain people to develop cirrhosis is still
unknown. The amount of alcohol ingested has been shown in epidemiological studies to be
the most important factor in determining the development of cirrhosis. Males drinking in
excess of 80 g and females in excess of 40 g of alcohol per day for 10 years are at a high
risk of developing cirrhosis. The alcohol content rather than the type of beverage is
important, and binge drinking is less injurious to the liver than continued daily
drinking.
Women are more susceptible to liver damage
than men. They are likely to develop cirrhosis at an earlier age, present at a later stage
and have more severe liver disease with more complications. Genetics may play a role in
the development of alcoholic liver disease, although no single genetic marker has been
identified. Patterns of alcohol drinking behavior are inherited. Alcohol is metabolized to
acetaldehyde by alcohol dehydrogenase and then to acetate by acetaldehyde dehydrogenase.
Genetic pleomorphism of the enzyme systems that metabolize alcohol, leading to different
rates of alcohol elimination, also contributes to the individual's susceptibility to
alcohol damage. Alcoholics with decreased acetaldehyde dehydrogenase activity develop
alcoholic liver disease at a lower cumulative intake than others. Malnutrition may play a
permissive role in producing alcohol hepatotoxicity. However, there is a threshold of
alcohol toxicity beyond which no dietary supplements can offer protection.
The spectrum of liver disease covers the
relatively benign steatosis to the potentially fatal alcoholic hepatitis and cirrhosis.
| 6.1 Alcoholic Fatty Liver |
page 503 |
Fatty liver is the most frequent hepatic
abnormality found in alcoholics. It is a toxic manifestation of ethanol ingestion,
appearing within three to seven days of excess alcohol intake. Metabolic changes
associated with ethanol ingestion result in increased triglyceride synthesis, decreased
lipid oxidation and impaired secretion by the liver. This results in the accumulation of
triglycerides in the hepatocytes, mainly in the terminal hepatic venular zone. In more
severe cases, the fatty change may be diffuse. The fat tends to accumulate as
macrovesicular (large droplets), rather than microvesicular (small droplets), which
represents mitochondrial damage. Fatty liver may occur alone or be part of the picture of
alcoholic hepatitis or cirrhosis.
Clinically, the patient is usually
asymptomatic, and the examination reveals a firm, smooth, enlarged liver. Occasionally the
fatty liver may be so severe that the patient is anorexic and nauseated, and has right
upper quadrant pain or discomfort. This usually follows a prolonged heavy alcoholic binge.
Liver function tests including bilirubin, albumin and INR are usually normal, although the
g-glutamyl transpeptidase (GGT) is invariably elevated while the aminotransferases and
alkaline phosphatase may be slightly increased. A fatty liver is usually detected by
ultrasound. Liver biopsy is required to make a definitive diagnosis. When fatty liver is
not associated with alcoholic hepatitis, its prognosis is excellent. Complete abstinence
from alcohol and a nutritious diet will lead to disappearance of the fat over four to six
weeks.
| 6.2 Alcoholic Hepatitis |
page 503 |
Alcoholic hepatitis may occur separately or
in combination with cirrhosis. There are all grades of severity. It is a condition
characterized by liver cell necrosis and inflammatory reaction. Histologically,
hepatocytes are swollen as a result of an increase in intracellular water secondary to
increase in cytosolic proteins. Steatosis, often of the macrovesicular type, is present.
Alcoholic hyaline (Mallory's) bodies are purplish red intracytoplasmic inclusions
consisting of clumped organelles and intermediate microfilaments. Polymorphs are seen
surrounding Mallory-containing cells and also within damaged hepatocytes. Collagen
deposition is usually present. It is maximal in the zone 3 and extends in a perisinusoidal
pattern to enclose hepatocytes, giving it a "chicken wiring" effect. Changes in the portal
triad are inconspicuous. Marked portal inflammation suggests an associated viral hepatitis
such as hepatitis C, whereas fibrosis suggests complicating chronic hepatitis. When the
acute inflammation settles, a varying degree of fibrosis is seen, which may eventually
lead to cirrhosis.
Clinically, mild cases of alcoholic
hepatitis are recognized on liver biopsy only in patients who present with a history of
alcohol abuse and abnormal liver enzymes. In the moderately severe case, the patient is
usually malnourished and presents with a two-to three-week prodrome of fatigue, anorexia,
nausea and weight loss. Clinical signs include a fever of <40ºC, jaundice and tender
hepatomegaly. In the most severe case, which usually follows a period of heavy drinking
without eating, the patient is gravely ill with fever, marked jaundice, ascites, and
evidence of a hyperdynamic circulation such as systemic hypotension and tachycardia.
Florid palmar erythema and spider nevi are present, with or without gynecomastia. Hepatic
decompensation can be precipitated by vomiting, diarrhea or intercurrent infection leading
to encephalopathy. Hypoglycemia occurs often and can precipitate coma. Gastrointestinal
bleeding is common, usually from a local gastric or duodenal lesion, resulting from the
combination of a bleeding tendency and portal hypertension. Signs of malnutrition and
vitamin deficiencies are common. Intake of moderate doses of acetaminophen in an alcoholic
may precipitate florid alcoholic hepatitis.
Laboratory abnormalities include elevations
of the aminotransferases, bilirubin, alkaline phosphatase and GGT. The aminotransferase
levels rarely exceed 300 IU/L, except in association with acetaminophen ingestion; the
AST/ALT ratio is usually >2. Hyperbilirubinemia can be quite marked, with levels
reaching 300 to 500 µmol/L, and is a reflection of the severity of the illness. The
increase in GGT is proportionally greater than that of alkaline phosphatase. There is also
leukocytosis of up to 20-25 x 109/L and increased INR/prothrombin time, which does not
respond to vitamin K. The serum albumin falls. Serum IgA is markedly increased, with IgG
and IgM raised to a lesser extent.
Patients with acute alcoholic hepatitis
often deteriorate during the first few weeks in hospital, with a mortality rate of 20-50%.
Bad prognostic indicators include spontaneous encephalopathy, markedly increased INR/PT
unresponsive to vitamin K and severe hyperbilirubinemia of greater than 350 µmol/L. The
condition may take one to six months to resolve, even with complete abstinence. Alcoholic
hepatitis progresses to cirrhosis in 25-30% of clinical episodes.
| 6.3 Alcoholic Cirrhosis |
page 504 |
Established cirrhosis is usually a disease
of middle age after the patient has had many years of drinking. Although there may be a
history of alcoholic hepatitis, cirrhosis can develop in apparently well-nourished,
asymptomatic patients. Occasionally the patient may present with end-stage liver disease
with malnutrition, ascites, encephalopathy and a bleeding tendency. A history of alcohol
abuse usually points to the etiology. Clinically, the patient is wasted. There may be
bilateral parotid enlargement and Dupuytren's contracture in alcohol abuse. The patient
may have palmar erythema and multiple spider nevi of chronic liver disease. Males develop
gynecomastia and small testes. Hepatomegaly is often present, affecting predominantly the
left lobe as a result of marked hypertrophy. There may be signs of portal hypertension,
which include splenomegaly, ascites and distended abdominal wall veins. At the late stage,
the liver may become shrunken and impalpable. There may be signs of alcohol damage in
other organ systems, such as peripheral neuropathy and memory loss from cerebral atrophy.
Alcoholic cirrhosis is also associated with renal problems, including IgA nephropathy,
renal tubular acidosis and the development of hepatorenal syndrome. There is an
association between hepatitis B and C and alcoholic cirrhosis.
Histologically, the cirrhosis is
micronodular. The degree of steatosis is variable and alcoholic hepatitis may or may not
be present. Pericellular fibrosis around hepatocytes is widespread. Portal fibrosis
contributes to the development of portal hypertension. There may be increased parenchymal
iron deposition. When parenchymal iron deposition is marked, genetic hemochromatosis has
to be excluded. With continued cell necrosis and regeneration, the cirrhosis may progress
to a macronodular pattern.
Biochemical abnormalities include a low
serum albumin, and elevated bilirubin and aminotransferases. AST and ALT levels rarely
exceed 300 IU/L and the AST/ALT ratio usually exceeds 2. GGT is disproportionately raised
with recent alcohol ingestion and is a widely used screening test for alcohol abuse. With
severe disease, the INR/PT may be increased. Portal hypertension results in hypersplenism
leading to thrombocytopenia, anemia and leukopenia. Other nonspecific serum changes in
acute and chronic alcoholics include elevations in uric acid, lactate and triglyceride,
and reductions in glucose and magnesium.
The prognosis of alcoholic cirrhosis
depends on whether the patient can abstain from alcohol; this in turn is related to family
support, financial resources and socioeconomic state. Patients who abstain have a
five-year survival rate of 60-70%, which falls to 40% in those who continue to drink.
Women have a shorter survival rate than men. Bad prognostic indicators include a low serum
albumin, increased INR/PT, low hemoglobin, encephalopathy, persistent jaundice and
azotemia. Zone 3 fibrosis and perivenular sclerosis are also unfavorable features.
Complete abstinence may not improve prognosis when portal hypertension is severe.
Hepatocellular carcinoma occurs in 10% of stable cirrhotics. This usually develops after a
period of abstinence when macronodular cirrhosis is present. It is usually fatal in six
months.
Early recognition of alcoholism is
important. Physicians should have a high index of suspicion when a patient presents with
anorexia, nausea, diarrhea, right upper quadrant tenderness and an elevated GGT. The most
important therapeutic measure is total abstinence from alcohol. Support groups and regular
follow-up can reinforce the need for abstinence. Withdrawal symptoms should be treated
with chlordiazepoxide or diazepam. A nutritious, well-balanced diet with vitamin
supplements should be instituted.
Alcoholic fatty liver responds to alcohol
withdrawal and a nutritious diet. Patients with severe alcoholic hepatitis should be
admitted to hospital and complications of liver failure treated appropriately. These
patients usually have significant metabolic abnormalities that have to be corrected.
Hyperglycemia is a common manifestation of chronic liver disease because of insulin
resistance, whereas hypoglycemia is a manifestation of (especially fulminant) hepatic
failure because of failure of gluconeogenesis and depletion of glycogen stores.
Hypomagnesemia and hypokalemia are common as a result of reduced dietary intake and
increased urinary excretion. Metabolic acidosis may be present, which may relate to the
failure to convert lactic acid to pyruvate as well as possible underlying ketoacidosis.
Specific treatments for alcoholic hepatitis include the use of corticosteroids. A recent
meta-analysis of 11 controlled trials showed a significant benefit of steroids for
patients with severe alcoholic hepatitis complicated by encephalopathy. Propylthiouracil
has been used to dampen the hepatic hypermetabolic state in alcoholic hepatitis, and may
reduce the two-year mortality rate. Testosterone and anabolic androgenic steroids have
been tried with conflicting results. Intravenous amino acid supplements have been given to
the severely protein malnourished with varying degrees of success. Oral supplementation is
the preferred route if the patient can tolerate a diet.
Cirrhosis is an irreversible process, and
therapy is directed at the complications of liver failure and portal hypertension,
although colchicine has been used as an antifibrotic agent without much success.
Portacaval shunts will reduce the risk of bleeding from esophageal varices, but the
establishment of a shunt is associated with a 30% incidence of hepatic encephalopathy (see
Section 11). Hepatic transplantation is a treatment option for patients with end-stage
alcoholic cirrhosis, although the ethical issues surrounding the use of such a scarce
resource for a self-inflicted disease still need to be settled. However, liver
transplantation is a reasonable option in patients with alcoholic liver disease providing
there is prolonged abstinence (at least six months), good social supports and no evidence
of severe damage to other organs due to alcoholism. In the centers that transplant in
cases of alcoholic cirrhosis, the results are comparable to those in patients with other
forms of cirrhosis. |